Hasil Pencarian - Florian Heil

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

    Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial oleh Cláudia S. Ferreira, Galina Babitzki, Irina Klaman, Oliver Krieter, Katharina Lechner, Johanna Bendell, Suzana Vega Harring, Florian Heil

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

    Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies oleh Florian Heil, Galina Babitzki, Alice Julien-Laferriere, Chia-Huey Ooi, Manuel Hidalgo, Christophe Massard, Maria Martinez-Garcia, Christophe Le Tourneau, Mark Kockx, Peter Gerber, Simona Rossomanno, Oliver Krieter, Angelika Lahr, Norbert Wild, Suzana Vega Harring, Katharina Lechner

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

    Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody oleh Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

    370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors oleh Josep Tabernero, Maurizio Ceppi, Victor Moreno, Michael Hettich, Miguel Sanmamed, Christina Claus, Tatiana Hernandez, Iben Spanggaard, Analia Azaro, Maria Martinez Garcia, Alejo Rodriguez-Vida, Florian Heil, Oliver Krieter, Oliver Grimm, Marta Canamero, Jose Duarte, Alexandra-Cristina Nica, Iakov Davydov, Chia-Huey Ooi, Christian Heichinger, Ernesto Guarin, Radoiane Helbaj, Tamara Tanos, Eveline Nueesch, Irene Moreno

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune re... oleh Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Miguel F. Sanmamed, Valentina Gambardella, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: